Latest studies
- Active not recruitingPHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations to treat advanced lung cancer. It compares two different drug mixes, each including chemotherapy, to see which works best and is safest for people with Stage IV or recurrent non-small cell lung cancer.
Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerMetastatic Non-small Cell Lung CancerRussia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study is looking at a new treatment called Ocrelizumab for primary progressive multiple sclerosis (PPMS). It compares Ocrelizumab to a dummy drug (placebo) to see how safe and effective it is for adults, including those who have had PPMS for a while.
Multiple Sclerosis, Primary ProgressiveRussia - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerRussia - Active not recruitingPHASE3
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
This study compares a new medicine, luspatercept, with a standard one, epoetin alfa, for people with a type of blood disorder called myelodysplastic syndromes (MDS). It aims to see if luspatercept can reduce the need for blood transfusions.
Myelodysplastic SyndromesRussia - Active not recruitingPHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
This study looks at a new way to treat muscle-invasive bladder cancer using a drug called Durvalumab alongside standard chemotherapy. It aims to see if this combination, given before and after surgery, can improve treatment outcomes and safety for patients.
Muscle Invasive Bladder CancerRussia - Active not recruitingPHASE1, PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
This study is looking at new combinations of medicines for HER2-positive breast cancer that has spread. It aims to see how safe and effective these combinations are in patients whose advanced breast cancer has come back or spread.
Metastatic Breast CancerRussia - Active not recruitingPHASE1, PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
This study is looking at a new combination of two drugs, Belantamab Mafodotin and Nirogacestat, for people with multiple myeloma that has come back or not responded to previous treatments. The main goal is to find a safe dose and see how well it works.
Multiple MyelomaRussia - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.
Hepatocellular CarcinomaRussia - Active not recruitingPHASE1, PHASE2
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
This study is testing a new liquid form of the medicine selumetinib for children aged 1 to 6 with a type of tumour linked to Neurofibromatosis Type 1 (NF1). It aims to find the right dose and check if it's safe and helps shrink the tumours.
Neurofibromatosis Type 1Russia - Active not recruitingPHASE3
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
This study is testing new treatments for liver cancer (hepatocellular carcinoma) in people who have had their cancer removed but are at high risk of it coming back. It compares a drug called durvalumab, alone or with bevacizumab, against a dummy treatment (placebo) to see if they can prevent the cancer from returning.
Hepatocellular CarcinomaRussia - Active not recruitingPHASE3
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
This study investigates how a medicine called semaglutide affects eye problems in people with type 2 diabetes over five years. Participants will get either semaglutide or a dummy medicine, injected once a week, along with their usual diabetes treatments.
Diabetes Mellitus, Type 2Russia - Recruiting
COVID-19 Vaccines Safety Tracking (CoVaST)
This study is looking at the side effects of COVID-19 vaccines in different groups of people, like healthcare workers and older adults. It aims to understand common side effects, who is more likely to get them, and any long-term effects. This helps build trust in vaccines.
Adverse Reaction to VaccineCOVID19 VaccineRussia - Active not recruitingPHASE3
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
This study is looking at a new treatment called isatuximab, combined with other treatments, for adults newly diagnosed with a type of blood cancer called multiple myeloma. It's for those who aren't able to have a stem cell transplant and aims to see if the new combination can help people live longer without their cancer getting worse.
Plasma Cell MyelomaRussia - Active not recruitingPHASE4
CINC424A2X01B Rollover Protocol
This study is for patients already taking ruxolitinib, or ruxolitinib with panobinostat, in a previous trial, and who are still benefiting. It lets them continue their treatment and helps researchers learn more about the long-term safety of these medications.
Primary MyelofibrosisPolycythemia VeraGraft Versus Host DiseaseAcute Myeloid LeukemiaRussia - Active not recruitingPHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This study allows some cancer patients who are already benefiting from certain treatments in another study to continue receiving that treatment. It’s for those who wouldn't be able to get the treatment otherwise, helping them keep accessing therapies that are working for them.
CancerRussia - Active not recruitingPHASE3
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
This study looks at new ways to treat advanced breast cancer that is sensitive to hormones and doesn't have too much HER2 protein. It compares a new drug called abemaciclib plus fulvestrant to fulvestrant alone, to see which helps patients live longer without their cancer growing.
Breast NeoplasmsRussia - RecruitingPHASE3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
This study offers ongoing access to a drug called ibrutinib for people already using it for certain blood cancers and conditions, who are still benefiting. It also helps gather more long-term information on how safe and effective ibrutinib is.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMantle Cell LymphomaFollicular LymphomaRussia - Active not recruitingPHASE2, PHASE3
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
This study is testing a new drug called imetelstat for certain types of Myelodysplastic Syndromes (MDS). It aims to see if the drug can help reduce the need for blood transfusions and is safe to use for people whose current treatment hasn't worked.
Myelodysplastic SyndromesRussia - Active not recruitingPHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
This study is testing new combinations of medicines for advanced kidney cancer (renal cell carcinoma). Its aim is to see if these new combinations work better and are safe compared to a standard treatment, for people who haven't had treatment for their advanced cancer before.
Carcinoma, Renal CellRussia - Active not recruitingPHASE4
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
This study offers ongoing access to ceritinib for patients already benefiting from it in another Novartis study. It's for people with ALK-positive cancers who, along with their doctor, believe continued treatment is helping them.
ALK Positive MalignanciesRussia - Recruiting
The K-Map Study, Global Prevalence of KC
The K-Map Study is looking for young people aged 6-23 to help understand how common a condition called keratoconus is. It uses a special camera to check eyes, even if they seem healthy, to see if more people have this eye problem than we currently think.
KeratoconusRussia - Active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
Ovarian CancerBreast CancerRussia - Active not recruitingPHASE3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
This study looks at a medicine called abemaciclib for people in the UK with a certain type of advanced lung cancer (non-small cell lung cancer) that has a specific gene change (KRAS mutation) and has come back after other treatments. It aims to see how safe and effective abemaciclib is.
Non Small Cell Lung CancerRussia - Active not recruitingPHASE3
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
This study is looking at a new medicine called guselkumab for people with psoriatic arthritis. It aims to see how well it reduces pain, swelling, and other symptoms compared to a dummy treatment, and if it helps improve their condition.
Arthritis, PsoriaticRussia - Active not recruitingPHASE3
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
This study is looking into new ways to treat advanced or recurrent womb cancer. We're testing a combination of medicines called durvalumab and olaparib, given after initial chemotherapy, to see if they can help patients live longer and better.
Endometrial NeoplasmsRussia - RecruitingPHASE4
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study looks at whether a special dye called gadolinium, used in MRI scans, affects how people move or think when they have it many times over five years. It compares people who get the dye with those who don't.
Motor FunctionCognitive FunctionContrast MediaRussia - Active not recruitingPHASE3
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
This study is testing if a medicine called selexipag can help children aged 2-17 with a serious lung condition called pulmonary hypertension. It aims to see if adding selexipag to their usual treatment can slow down the disease compared to a dummy medicine.
Hypertension, PulmonaryRussia - Active not recruitingPHASE3
A Study of Daratumumab
This study offers ongoing access to specific treatments for people with multiple myeloma or smouldering multiple myeloma who have already benefited from them in previous studies. It helps ensure continued care and collects long-term safety information.
Multiple MyelomaRussia - Active not recruitingPHASE3
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This study compares a new drug, alectinib, with standard chemotherapy for people with a certain type of lung cancer (ALK-positive non-small cell lung cancer) after surgery. We want to see if alectinib is better at stopping the cancer from coming back and if it's safe.
Carcinoma, Non-Small-Cell LungRussia - Active not recruiting
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
This study looks at how a medicine called darolutamide (Nubeqa) works in real life for men with prostate cancer that hasn't spread and has stopped responding to other treatments. Doctors have already decided these men will receive darolutamide.
Prostate CancerRussia - Recruiting
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
This study looks at how well Octapharma's treatments (Nuwiq, Octanate, and Wilate) work in real life for children and young people with severe haemophilia A who haven't had much treatment before. It checks their safety and how they are used.
Haemophilia ARussia - Active not recruitingPHASE3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
This study looks at a new drug, erdafitinib, for advanced bladder cancer that has specific genetic changes. Researchers want to see if it works better than standard treatments like chemotherapy or pembrolizumab after previous treatments haven't helped enough.
Urothelial CancerRussia - Active not recruitingPHASE3
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is looking at how well two new drugs, enfortumab vedotin and pembrolizumab, work together to treat advanced bladder cancer that has spread. It compares them to standard chemotherapy treatments to see if they are a better option.
Urothelial CancerRussia - Active not recruitingPHASE3
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
This study looks at a new combination of treatments for a type of advanced lung cancer. It compares a drug called amivantamab plus standard chemotherapy to chemotherapy alone, to see if the combination works better at stopping the cancer from growing.
Carcinoma, Non-Small-Cell LungRussia - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
Crohn's Disease (CD)Russia - RecruitingPHASE3
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
This study looks at a medicine called baricitinib for children aged 1 to 17 with Juvenile Idiopathic Arthritis (JIA). It checks if the medicine is safe and helps treat their JIA. Participants have been in previous baricitinib studies for JIA.
Juvenile Idiopathic ArthritisRussia - Active not recruitingPHASE3
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at two new drug combinations, amivantamab and lazertinib, compared to a standard drug, osimertinib, for people in the UK with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation).
Carcinoma, Non-Small-Cell LungRussia - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCRussia - Active not recruitingPHASE3
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study looks at a new drug, trastuzumab deruxtecan, for advanced breast cancer that is HER2-low and hormone receptor positive. We want to see if it works better and is safer than standard chemotherapy for people whose cancer has progressed after other treatments.
Advanced or Metastatic Breast CancerRussia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This study looks at a new, higher dose of ocrelizumab for people with primary progressive multiple sclerosis (PPMS). Researchers want to see if this dose is safe and works better than the current approved dose to slow down the disease.
Multiple SclerosisRussia - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerRussia - Active not recruitingPHASE3
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This study is testing a new drug, MRTX849 (adagrasib), for advanced lung cancer with a specific gene change (KRAS G12C). It compares it to a standard treatment, docetaxel, for people whose cancer has already been treated.
Metastatic Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerRussia - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsRussia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
This study investigates a new treatment, CAEL-101, for a serious heart condition called AL amyloidosis. Researchers want to see if CAEL-101 can help patients live longer and reduce hospital stays, alongside their usual medicine, compared to a dummy drug.
AL AmyloidosisRussia - Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's DiseaseRussia - Active not recruitingPHASE3
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is looking at a new medicine called acalabrutinib for chronic lymphocytic leukaemia (CLL). It compares acalabrutinib to usual treatments to see which works best for people whose CLL has come back or hasn't responded to previous treatment.
Chronic Lymphocytic LeukemiaRussia - Active not recruitingPHASE3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This study looks at the long-term safety and effectiveness of a medicine called ocrelizumab for people with Multiple Sclerosis (MS). It's for people already taking part in other ocrelizumab studies, to see how the treatment works over a longer time.
Multiple SclerosisRussia - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
Non Small Cell Lung Cancer NSCLCRussia - Active not recruitingPHASE2
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
This study is checking if the benefits of bepirovirsen for Hepatitis B last over time. It's for people who previously took part in a bepirovirsen trial and showed good results. No new treatment is given in this follow-up study, just monitoring.
Hepatitis BRussia - Active not recruitingPHASE3
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
This study looks at adding a new drug, Apalutamide, to standard hormone therapy for men with prostate cancer that has spread. We want to see if this combination helps patients live longer or keeps their cancer from getting worse.
Prostate CancerRussia